
Sign up to save your podcasts
Or


This episode was recorded on December 18, 2020.
To claim credit visit: https://ce.mayo.edu/covid19podcast
Guest: Gregory A. Poland, M.D. (@drgregpoland)
Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006)
It is projected that by March of 2021 1:700 Americans will have died of COVID-19. The historic pace of COVID-19 vaccine development was made possible by the countless sacrifices of many individuals across healthcare, research, health and human services, the Department of Defense, and other key sectors. This interprofessional collaboration required many to set life aside and work tirelessly to bring an effective vaccine to market, quickly. While mRNA vaccines have been in development since the 1990s, the COVID-19 vaccine efficacy rate of 95-100% across studied ages, race and ethnicities, and comorbidities is unprecedented. The questions left to answer are, how long will the efficacy last? In larger population studies, what is the safety/allergy/hypersensitivity profile? What impact does the vaccine have on asymptomatic carrier spread? Who shouldn’t get the vaccine? Dr. Greg Poland breaks down everything you need to know about the mRNA COVID-19 vaccines.
Additional Resources:
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
By Mayo Clinic4.4
268268 ratings
This episode was recorded on December 18, 2020.
To claim credit visit: https://ce.mayo.edu/covid19podcast
Guest: Gregory A. Poland, M.D. (@drgregpoland)
Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006)
It is projected that by March of 2021 1:700 Americans will have died of COVID-19. The historic pace of COVID-19 vaccine development was made possible by the countless sacrifices of many individuals across healthcare, research, health and human services, the Department of Defense, and other key sectors. This interprofessional collaboration required many to set life aside and work tirelessly to bring an effective vaccine to market, quickly. While mRNA vaccines have been in development since the 1990s, the COVID-19 vaccine efficacy rate of 95-100% across studied ages, race and ethnicities, and comorbidities is unprecedented. The questions left to answer are, how long will the efficacy last? In larger population studies, what is the safety/allergy/hypersensitivity profile? What impact does the vaccine have on asymptomatic carrier spread? Who shouldn’t get the vaccine? Dr. Greg Poland breaks down everything you need to know about the mRNA COVID-19 vaccines.
Additional Resources:
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

136 Listeners

319 Listeners

699 Listeners

496 Listeners

250 Listeners

259 Listeners

3,344 Listeners

1,159 Listeners

195 Listeners

90 Listeners

513 Listeners

364 Listeners

12 Listeners

252 Listeners

18 Listeners

15 Listeners

9 Listeners

430 Listeners

369 Listeners

45 Listeners

14 Listeners